Rett syndrome

Recent articles

Headshots of Yale researchers Yong-Hui Jiang and Jiangbing Zhou.

Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions

Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.

By Natalia Mesa
3 June 2026 | 11 min read
DNA strand.

Exon-skipping approach boosts levels of key Rett syndrome protein

Deleting a small region of the MECP2 gene partially restored function in neurons derived from people with Rett-associated variants.

By Giorgia Guglielmi
20 March 2026 | 5 min read
A mouse sits on a gloved hand.

Molecular changes after MECP2 loss may drive Rett syndrome traits

Knocking out the gene in adult mice triggered up- and down-regulated expression of myriad genes weeks before there were changes in neuronal function.

By Chloe Williams
20 March 2025 | 5 min read
Research image of frog cells.

Many autism-linked proteins influence hair-like cilia on human brain cells

The finding may help explain autism’s association with multiple co-occurring conditions that involve cilia defects.

By Charles Q. Choi
9 January 2025 | 4 min read
Photograph of a syringe.

What’s next for brain-directed gene therapy after death in Neurogene trial

The incident highlights that viral vectors can trigger deadly immune responses even when delivered directly to the nervous system.

By Calli McMurray
26 November 2024 | 6 min read
Research image of toxoplasma gondii showing cysts it creates as well as the MECP2 protein that it can deliver to neurons.

Parasite-based tool delivers MECP2 and other proteins to neurons

A method that uses a common brain parasite could help replenish the proteins deficient in Rett syndrome and other conditions.

By Giorgia Guglielmi
12 September 2024 | 4 min read
A digital rendering of a strand of RNA

New RNA editor boasts increased versatility, safety

The “PRECISE” technique reprograms cells in a way that, unlike DNA editors, avoids potentially permanent off-target effects.

By Charles Q. Choi
11 April 2024 | 4 min read
Illustration of a sheet of red and white pills, with the red pills arranged in the form of a question mark.

New template streamlines sharing clinical trial results

This month’s Going on Trial newsletter explores a new tool for communicating with clinical trial participants and their families, among other drug development news.

By Calli McMurray
31 October 2023 | 7 min read
Illustration of a sheet of red and white pills, with the red pills arranged in the form of a question mark.

Trials test utility of EEG biomarkers for autism-related conditions

This month’s Going on Trial newsletter dives into an electroencephalography biomarker that could track the efficacy of treatments for dup15q and Angelman syndromes, among other drug development news.

By Calli McMurray
31 August 2023 | 7 min read
A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.

How organ-on-a-chip models can help drug development

This month’s Going on Trial newsletter explores how organ-on-a-chip models could smooth the transition from preclinical to clinical trials, among other drug development news.

By Calli McMurray
31 July 2023 | 5 min read

Explore more from The Transmitter

Research image of cell-surface protein LPHN2.

‘Push-pull’ recipe for neural wiring used in multiple brain regions

A versatile pair of proteins steers neurons toward their targets and helps establish the brain’s sensory maps, new studies suggest.

By Holly Barker
5 June 2026 | 5 min read
Research image showing dopamine level spikes.

Reward-learning algorithm hardwired into dopamine circuit

The finding bolsters the canonical model of reward prediction error, which has come under scrutiny in recent years.

By Natalia Mesa
5 June 2026 | 5 min read
Burke Neurological Institute.

Exclusive: Brain and spinal cord institute halts research, citing funding problems

The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.

By Lauren Schenkman
4 June 2026 | 5 min read